NXTC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
15.1M
+49.4%
10.1M
+3.6%
9.8M
+9.1%
8.9M
-67.2%
27.3M
R&D
7.4M
+8.6%
6.8M
+0.5%
6.8M
+10.8%
6.1M
-74.5%
24.1M
SG&A
2.6M
-20.8%
3.3M
+10.6%
3.0M
+5.3%
2.8M
-12.2%
3.2M
Operating Income
-15094000
-49.4%
-10105000
-3.6%
-9757000
-9.1%
-8945000
+67.2%
-27292000
EBITDA
-9745000
+0.8%
-9822000
-4.6%
-9392000
-11.7%
-8412000
+68.4%
-26659000
Net Income
-14892000
-52.0%
-9796000
-3.8%
-9436000
-9.4%
-8624000
+67.8%
-26808000
EPS (Basic)
$-2.80
-49.7%
$-1.87
+21.1%
$-2.37
+26.4%
$-3.22
+71.5%
$-11.29
EPS (Diluted)
$-2.80
-49.7%
$-1.87
+21.1%
$-2.37
+26.4%
$-3.22
+71.5%
$-11.29
Shares (Diluted)
5.3M
+1.3%
5.2M
+31.5%
4.0M
+48.9%
2.7M
+12.7%
2.4M
NextCure (NXTC) โ€” Financials